Table 3.

Adverse events of each chemotherapeutic regimen

nab-PTX followed by FEC (n = 50)
Adverse events	nab-PTX		FEC
	All Grade n (%)	Grade 3 n (%)	All Grade n (%)	Grade 3 n (%)
Neutropenia	3 (6.0)	2 (4.0)	6 (12.0)	3 (6.0)
Anemia	0	0	2 (4.0)	2 (4.0)
Hepatopathy	5 (10.0)	1 (2.0)	0	0
Stomatitis	2 (4.0)	0	12 (24.0)	1 (2.0)
Fatigue	4 (8.0)	0	21 (42.0)	1 (2.0)
Constipation	3 (6.0)	0	8 (16.0)	0
Nausea	1 (2.0)	0	13 (26.0)	1 (2.0)
Arthralgia	26 (52.0)	0	1 (2.0)	0
Peripheral neuropathy	48 (96.0)	0	24 (48.0)	0
Rash	11 (22.0)	3 (6.0)	2 (4.0)	0
Anaphylactic shock	0	0	0	0
Keratitis	0	0	1 (2.0)	0
Fever	4 (8.0)	0	1 (2.0)	0
Hand foot syndrome	1 (2.0)	0	2 (4.0)	0
Diarrhea	0	0	3 (6.0)	0
Edema	1 (2.0)	0	2 (4.0)	0
Blurred vision	1 (2.0)	0	1 (2.0)	0
Myalgia	1 (2.0)	0	0	0

FEC: 5-fluorouracil, epirubicin, and cyclophosphamide, nab-PTX: nanoparticle albumin-bound paclitaxel.